A mutant of the major apple allergen, Mal d 1, demonstrating hypo‐allergenicity in the target organ by double‐blind placebo‐controlled food challenge

Background Allergen‐specific immunotherapy for food allergy has been hindered by severe side‐effects in the past. Well‐characterized hypo‐allergenic recombinant food allergens potentially offer a safe solution.

[1]  P. Briza,et al.  Mutational Analysis of Amino Acid Positions Crucial for IgE-Binding Epitopes of the Major Apple (Malus domestica) Allergen, Mal d 1 , 2005, International Archives of Allergy and Immunology.

[2]  G. Marzban,et al.  Localisation and distribution of the major allergens in apple fruits , 2005 .

[3]  C. Radauer,et al.  Lab scale and medium scale production of recombinant allergens in Escherichia coli. , 2004, Methods.

[4]  D. Strachan,et al.  Increasing hospital admissions for systemic allergic disorders in England: analysis of national admissions data , 2003, BMJ : British Medical Journal.

[5]  A. Knulst,et al.  The distribution of individual threshold doses eliciting allergic reactions in a population with peanut allergy. , 2002, The Journal of allergy and clinical immunology.

[6]  R. Van Ree,et al.  The range of minimum provoking doses in hazelnut‐allergic patients as determined by double‐blind, placebo‐controlled food challenges , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[7]  M. Andersson,et al.  Nasal challenges with recombinant derivatives of the major birch pollen allergen Bet v 1 induce fewer symptoms and lower mediator release than rBet v 1 wild‐type in patients with allergic rhinitis , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[8]  S. Scheurer,et al.  Current Understanding of Cross‐Reactivity of Food Allergens and Pollen , 2002, Annals of the New York Academy of Sciences.

[9]  R. Helm,et al.  Modification of Peanut Allergen Ara h 3: Effects on IgE Binding and T Cell Stimulation , 2002, International Archives of Allergy and Immunology.

[10]  R. Valenta,et al.  Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE‐binding capacity: candidates for grass pollen‐specific immunotherapy , 2002, European journal of immunology.

[11]  T. Eriksson,et al.  T cell responses to recombinant isoforms, synthetic peptides and a mutant variant of Lep d 2, a major allergen from the dust mite Lepidoglyphus destructor , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[12]  P. Colombo,et al.  Hypoallergenic Variants of the Parietaria judaica Major Allergen Par j 1: A Member of the Non-Specific Lipid Transfer Protein Plant Family , 2001, International Archives of Allergy and Immunology.

[13]  R. Helm,et al.  Engineering, Characterization and in vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy , 2001, International Archives of Allergy and Immunology.

[14]  S. Vieths,et al.  Double‐blind, placebo‐controlled food challenge with apple , 2001, Allergy.

[15]  Oster,et al.  Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild‐type by skin prick and intradermal testing: results obtained in a French population , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[16]  E. Knol,et al.  Reactivity to IgE‐dependent histamine‐releasing factor is due to monomeric IgE , 2000, Allergy.

[17]  H. Sampson,et al.  Food allergy. Part 1: immunopathogenesis and clinical disorders. , 1999, The Journal of allergy and clinical immunology.

[18]  A. Burks,et al.  Modification of a Major Peanut Allergen Leads to Loss of IgE Binding , 1999, International Archives of Allergy and Immunology.

[19]  J Bousquet,et al.  Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. , 1998, The Journal of allergy and clinical immunology.

[20]  G. Casari,et al.  Modulation of IgE reactivity of allergens by site‐directed mutagenesis: potential use of hypoallergenic variants for immunotherapy , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  H. Nelson,et al.  Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. , 1997, The Journal of allergy and clinical immunology.

[22]  P. Parren,et al.  Production of a mouse/human chimeric IgE monoclonal antibody to the house dust mite allergen Der p 2 and its use for the absolute quantification of allergen-specific IgE. , 1997, The Journal of allergy and clinical immunology.

[23]  K. Hoffmann‐Sommergruber,et al.  High-level expression and purification of the major birch pollen allergen, Bet v 1. , 1997, Protein expression and purification.

[24]  K. Hoffmann‐Sommergruber,et al.  Cloning and sequencing of Mal d 1, the major allergen from apple (Malus domestica), and its immunological relationship to Bet v 1, the major birch pollen allergen. , 1995, Biochemical and biophysical research communications.

[25]  J. Akkerdaas,et al.  Multiplicity of cross‐reactive epitopes on Bet v I as detected with monoclonal antibodies and human IgE , 1995, Allergy.

[26]  T. Kuijpers,et al.  Stimulation of human basophils results in homotypic aggregation. A response independent of degranulation. , 1993, Journal of immunology.

[27]  A. Frew,et al.  Position Paper: Allergen standardization and skin tests , 1993 .

[28]  C. Liisberg,et al.  Precise area determination of skin‐prick tests: validation of a scanning device and software for a personal computer , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  H. Nelson,et al.  Treatment of peanut allergy with rush immunotherapy. , 1992, The Journal of allergy and clinical immunology.

[30]  H. Jansen,et al.  Discrepancies between the skin test and IgE antibody assays: study of histamine release, complement activation in vitro, and occurrence of allergen-specific IgG. , 1988, The Journal of allergy and clinical immunology.

[31]  R. Aalberse,et al.  Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. , 1981, The Journal of allergy and clinical immunology.

[32]  R. Siraganian.  Refinements in the automated fluorometric histamine analysis system. , 1975, Journal of immunological methods.

[33]  R. Mulcahy,et al.  PRIMARY PREVENTION , 1975, The Lancet.

[34]  J. Freeman.  " RUSH " INOCULATION, WITH SPECIAL REFERENCE TO HAY-FEVER TREATMENT. , 1930 .

[35]  Steve L Taylor,et al.  Factors affecting the determination of threshold doses for allergenic foods: how much is too much? , 2002, The Journal of allergy and clinical immunology.

[36]  S. Vieths,et al.  Characterization of Mal d 1, the 18-kD major apple allergen, at the molecular level. , 1996, Monographs in allergy.